Shenzhen Neoimmune and Maijie Medical reached a strategic cooperation

2023-05-31 16:52:28 Neoimmune 606

Shenzhen Neoimmune Co., Ltd and Maijie Medical reached a strategic cooperation to jointly promote the clinical application of immune panel sequencing technology

 

Recently, China's leading innovative enterprise of companion diagnostics, Maijie Translational Medicine Research (Suzhou) Co., Ltd. (hereinafter referred to as "Maijie Medical") reached a strategic cooperation agreement with Shenzhen Pan-Cause Medical Co., Ltd. (hereinafter referred to as "Shenzhen Neoimmune Co., Ltd"), a leading domestic immunoomics testing service company. The two parties will give full play to their respective advantages to promote the application of NGS sequencing technology in the clinical trial, scientific research and clinical diagnosis and treatment of new drugs, in order to achieve the purpose of complementary advantages and common development, and the two sides will establish a collaborative cooperation mechanism to maximize the mobilization of resources and actively promote the implementation of the project.

 

As a leader in the overall solution of companion diagnostics, Maijie Medical has three major businesses of comprehensive translational medicine technology to support drug clinical transformation, companion diagnostic product (CDx) development and medication guidance and testing, based on genomics, proteomics, cytomics, pathomics, big data and AI and other integrated technology platforms, first-class product development team and perfect R&D process, as well as a perfect quality system. Gene therapy enables clinical translational research of drugs and develops corresponding companion diagnostic products to support the precision use of drugs after marketing. Shenzhen Neoimmune Co., Ltd has long been rooted in the field of hematological tumors, mainly engaged in the treatment of leukemia, lymphoma and other diseases, monitoring and construction of high-efficiency immunotherapy drug screening platform, committed to the development of high-throughput reading and writing T and B lymphocyte receptor spectrum key technologies, the development of clinical testing products and help screen TCRT and antibody and other therapeutic drugs.

This collaboration focuses on the field of hematological oncology and is committed to promoting the clinical application of high-sensitivity MRD detection technology. With the help of the NEOMRD® hematologic minimal residual disease (MRD) detection product independently developed by Shenzhen Neoimmune Co., Ltd, Maijie Medical will provide clinical trial testing for innovative pharmaceutical companies. In this cooperation, both parties will give full play to their respective advantages to achieve full-process coverage from experiment to information in the field of immunopanel sequencing, further improving the speed of detection and benefiting more patients.

Starting from the cooperation in hematological tumor MRD testing, the two parties will jointly explore and develop better detection technologies and immunotherapy drugs in the future, serve the majority of patients, and make life full of hope.

 

About Shenzhen Neoimmune Co., Ltd

Shenzhen Neoimmune Co., Ltd is a leading global provider of data and technology in the field of immunology precision medicine, and has successively been recognized as a national high-tech enterprise, Shenzhen innovative small and medium-sized enterprise, and Shenzhen science and technology small and medium-sized enterprise. Relying on the NGS technology of the immune group, Shenzhen Neoimmune Co., Ltd provides product solutions for the whole process of disease discovery, detection, monitoring and treatment, and has long been rooted in the field of hematological tumors, mainly engaged in the treatment, monitoring and construction of high-efficiency immunotherapy drug screening platform for leukemia, lymphoma and other diseases. As the world's leading immunoomics platform company, in the past 10 years, Shenzhen Neoimmune Co., Ltd has accumulated the largest immunomics information of scientific research/clinical samples in China, providing data support for tumor TCR and effective antibody screening, as well as immunological library products such as tumor early screening, immunotherapy accompanying diagnosis, and MRD monitoring. The founding team has published more than 70 high-level papers in immunoomics and applied for more than 20 patents. "Quantifying immunity and escorting health" is the principle and purpose that Pan-Cause has always adhered to.

 

About Maijie Medicine

Maijie Translational Medicine Research (Suzhou) Co., Ltd. (hereinafter referred to as Maijie Medical) was established in 2013, formerly known as QIAGEN Translational Medicine Research Center. As a leader in total solutions for companion diagnostics, Maijie Medical has three major businesses: comprehensive translational technology to support drug clinical translation, companion diagnostic product (CDx) development and medication guidance testing. Based on integrated technology platforms such as genomics, proteomics, cytomics, pathomics, big data and AI, first-class product development team and perfect R&D process, and perfect quality system (covering CAP, ISO13485, CNAS/ISO17025, GMP and GSP), Maijie Medical focuses on targeted therapy, immunotherapy and cell/gene therapy enabling drug clinical translational research and develops corresponding companion diagnostic products to support post-marketing precision medicine. Maijie Medical has cooperated with 300+ innovative pharmaceutical companies and technology companies around the world, and has developed and validated hundreds of biomarkers and methodologies, supporting hundreds of drug clinical trials. Up to now, a total of 20+ products have been approved by the drug administration, covering solid tumors and hematological tumors, including the first approved JAK2-V617F mutation detection kit and PDL-1 detection kit for immunotherapy; As well as 8 CE marked products and more than 10 other clinically in-demand products. At the same time, Maijie Medical has more than 40 CDx/IVD product pipelines under development, 10 of which are in clinical trials, and an AI-assisted interpretation software is being declared, which is expected to obtain a Class II registration certificate by the end of the year. Based on the original integrated business model, Maijie Medical has rapidly developed into an innovative enterprise of Chinese companion diagnostic overall solutions, solving the pain points of innovative drug research and development and patients, and helping precision medicine.


Contact Us

8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.

TEL: 0755-8453-4802

EMAIL

query@neoimmune.cn